A $25 Billion Opportunity: Exploring the Enormous Market Impact of Deucravacitinib 2024-08-01
Deucravacitinib has emerged as a groundbreaking treatment for moderate-to-severe plaque psoriasis. As we at Unibest keep up with the current pharamceutical blockbusters, we're excited to explore the potential of this novel drug in the enormous oral systemic psoriasis drug market.A Milestone in Deut
Read More